よむ、つかう、まなぶ。
会議資料 (247 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00044.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第66回 12／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-144
conditioning before allogeneic haemopoietic cell transplantation in
patients with acute myeloid leukaemia in first complete remission: a
prospective, open-label randomised phase 3 trial. Lancet Oncol.
2012;13:1035–44. 11)
Blaise D, et al. Randomized study of 2 reduced-intensity conditioning
strategies for human leukocyte antigen-matched, related allogeneic
peripheral blood stem cell transplantation: prospective clinical and
socioeconomic evaluation. Cancer. 2013;119:602–11. 12)
Flu/Cy
根拠文献の記なし
FLAG-IDA
根拠文献の記なし
Flu/Bu2
Blaise D, et al. Randomized study of 2 reduced-intensity conditioning
strategies for human leukocyte antigen-matched, related allogeneic
peripheral blood stem cell transplantation: prospective clinical and
socioeconomic evaluation. Cancer. 2013;119:602–11. 12)
Beelen DW, et al. Treosulfan or busulfan plus fludarabine as
conditioning treatment before allogeneic haemopoietic stem cell
transplantation for older patients with acute myeloid leukaemia
or myelodysplastic syndrome (MC-FludT.14/L): a randomised, noninferiority, phase 3 trial. Lancet Haematol. 2020;7:e28–39.5)
Flu/Mel
1)
Scott BL, et al. Myeloablative versus reduced-intensity hematopoietic
cell transplantation for acute myeloid leukemia and myelodysplastic
syndromes. J Clin Oncol. 2017;35:1154–61. 6)
2)
Eapen M, et al.Hematopoietic cell transplant for acute myeloid
leukemia and myelodysplastic syndrome: conditioning regimen
intensity. Blood Adv. 2018;2:2095–103. 13)
3)
Shimoni A, et al. Comparison between two fludarabine-based
reduced-intensity conditioning regimens before allogeneic
hematopoietic stem-cell transplantation: fludarabine/melphalan is
associated with higher incidence of acute graft-versus-host disease
and non-relapse mortality and lower incidence of relapse than
fludarabine/busulfan. Leukemia. 2007;21:2109–16. 14)
Flu/Treo
Beelen DW, et al. Treosulfan or busulfan plus fludarabine as
5
247 / 451
conditioning before allogeneic haemopoietic cell transplantation in
patients with acute myeloid leukaemia in first complete remission: a
prospective, open-label randomised phase 3 trial. Lancet Oncol.
2012;13:1035–44. 11)
Blaise D, et al. Randomized study of 2 reduced-intensity conditioning
strategies for human leukocyte antigen-matched, related allogeneic
peripheral blood stem cell transplantation: prospective clinical and
socioeconomic evaluation. Cancer. 2013;119:602–11. 12)
Flu/Cy
根拠文献の記なし
FLAG-IDA
根拠文献の記なし
Flu/Bu2
Blaise D, et al. Randomized study of 2 reduced-intensity conditioning
strategies for human leukocyte antigen-matched, related allogeneic
peripheral blood stem cell transplantation: prospective clinical and
socioeconomic evaluation. Cancer. 2013;119:602–11. 12)
Beelen DW, et al. Treosulfan or busulfan plus fludarabine as
conditioning treatment before allogeneic haemopoietic stem cell
transplantation for older patients with acute myeloid leukaemia
or myelodysplastic syndrome (MC-FludT.14/L): a randomised, noninferiority, phase 3 trial. Lancet Haematol. 2020;7:e28–39.5)
Flu/Mel
1)
Scott BL, et al. Myeloablative versus reduced-intensity hematopoietic
cell transplantation for acute myeloid leukemia and myelodysplastic
syndromes. J Clin Oncol. 2017;35:1154–61. 6)
2)
Eapen M, et al.Hematopoietic cell transplant for acute myeloid
leukemia and myelodysplastic syndrome: conditioning regimen
intensity. Blood Adv. 2018;2:2095–103. 13)
3)
Shimoni A, et al. Comparison between two fludarabine-based
reduced-intensity conditioning regimens before allogeneic
hematopoietic stem-cell transplantation: fludarabine/melphalan is
associated with higher incidence of acute graft-versus-host disease
and non-relapse mortality and lower incidence of relapse than
fludarabine/busulfan. Leukemia. 2007;21:2109–16. 14)
Flu/Treo
Beelen DW, et al. Treosulfan or busulfan plus fludarabine as
5
247 / 451